CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) announced today that the company has begun enrollment in a world-wide post-marketing clinical trial evaluating the efficacy and safety of treating pediatric male patients with mild Fabry disease symptoms with a low-dose regimen of Fabrazyme® (agalsidase beta). Data from the “Fabrazyme: Intervening Early at a Lower Dose (FIELD)” study may support supplemental submissions to regulatory agencies seeking additional dosing options that facilitate early treatment for Fabry disease.
